New trial
Phase 1 trial of [68Ga]Ga DOTA-5G, somatostatin receptor-targeted PET/CT diagnostic agent.
- Trial ID
- NCT07020806 on ClinicalTrials.gov
- Cancer type
- Breast Cancer
- Stage of research
- First-in-human
- Published in
- New in Oncology - June 27, 2025
This prospective trial at University of California, Davis evaluates [68Ga]Ga DOTA-5G PET/CT imaging after a 5 mCi injection in patients with advanced invasive lobular breast cancer. The study examines the safety and performance of this diagnostic agent, and findings may inform future imaging protocols in this patient population.
More in breast cancer
-
Trial result · Oct 22, 2026 · NCT02364557
NRG-BR002: Metastasis-directed ablation (SBRT/surgery) fails to extend PFS in oligometastatic breast cancer on 1L systemic therapy -
Trial result · Oct 22, 2026 · NCT05963984
Samuraciclib + fulvestrant shows higher clinical benefit and numerically longer PFS after CDK4/6 inhibition in randomized Phase 2 breast cancer trial -
Trial result · Oct 15, 2026 · NCT05306340
Giredestrant (oral SERD) + everolimus improves PFS after CDK4/6 inhibition, with the strongest benefit in ESR1-mutated breast cancer -
Trial result · Oct 15, 2026 · NCT02264678
Ceralasertib (ATR inhibitor) + Olaparib (PARP inhibitor) hits 37.8% ORR in PARPi‑naïve BRCA‑mut HER2‑neg breast cancer -
New trial · Oct 15, 2026 · NCT07844759
Pilot study tests single-fraction stereotactic radiation plus endocrine therapy without lumpectomy in early breast cancer